CroíValve raises $16m in Series B for heart valve treatment device
The funding will finance an early feasibility study of its flagship product Duo to evaluate its safety and performance in treating tricuspid regurgitation.
CroíValve, a medtech start-up that spun out of Trinity College Dublin, has closed a $16m Series B funding round led by the MedTech and Irrus Syndicates. Headquartered in Dublin, CroíValve is developing a device to fix the tricuspid heart valve without the need for surgery. Tricuspid regurgitation (TR) happens when the tricuspid valve in your heart doesn’t seal shut entirely, which can cause blood to flow backwards. This can change the heart’s structure over time, leading to permanent heart damage and a variety of other problems.
